CAJ | 학술논문

目的：观察芪苈强心胶囊治疗老年收缩性心力衰竭的临床疗效。方法选取年龄≥65岁的老年收缩性心力衰竭患者196例，随机分为观察组116例和对照组80例。对照组给予常规服用利尿剂、血管紧张素转换酶抑制剂（ACEI）或血管紧张素Ⅱ受体阻滞剂（ARB）、β-受体阻滞剂、洋地黄制剂、硝酸酯类等药物治疗。观察组在对照组治疗基础上给予芪苈强心胶囊口服，于入组时及治疗后8周检测肝功能、肾功能、心肌酶、临床疗效、6分钟步行试验（6 MWT）、左室射血分数（LVEF）、左心室舒张末期内径（LVEDD）、血清N末端脑钠肽前体（NT-proBNP）的变化。结果观察组总有效率优于常规治疗组（92．2％vs．83．85，χ2＝6．852， P ＜0．05）；2组LVEF、NT-proBNP均较治疗前好转（ t 对＝4．431、51．213， t 观＝6．132、71．663， P均＜0．05），观察组NT-proBNP水平较对照组降低明显（ P ＜0．05）；2组肝功能、肾功能、心肌酶治疗前后变化差异均无统计学意义（ P ＞0．05）。结论芪苈强心胶囊有效改善老年收缩性心力衰竭患者的临床症状和心功能，无用药不良反应发生，值得临床推广应用。
목적：관찰기력강심효낭치료노년수축성심력쇠갈적림상료효。방법선취년령≥65세적노년수축성심력쇠갈환자196례，수궤분위관찰조116례화대조조80례。대조조급여상규복용이뇨제、혈관긴장소전환매억제제（ACEI）혹혈관긴장소Ⅱ수체조체제（ARB）、β-수체조체제、양지황제제、초산지류등약물치료。관찰조재대조조치료기출상급여기력강심효낭구복，우입조시급치료후8주검측간공능、신공능、심기매、림상료효、6분종보행시험（6 MWT）、좌실사혈분수（LVEF）、좌심실서장말기내경（LVEDD）、혈청N말단뇌납태전체（NT-proBNP）적변화。결과관찰조총유효솔우우상규치료조（92．2％vs．83．85，χ2＝6．852， P ＜0．05）；2조LVEF、NT-proBNP균교치료전호전（ t 대＝4．431、51．213， t 관＝6．132、71．663， P균＜0．05），관찰조NT-proBNP수평교대조조강저명현（ P ＜0．05）；2조간공능、신공능、심기매치료전후변화차이균무통계학의의（ P ＞0．05）。결론기력강심효낭유효개선노년수축성심력쇠갈환자적림상증상화심공능，무용약불량반응발생，치득림상추엄응용。
Objective To observe the therapeutic effect of Qiliqiangxin capsule in the treatment of senile congestive heart failure .Methods Selected 196 cases of age more than or equal 65 elderly patients with systolic heart failure , they were randomly divided to observation group (116 cases) and control group (80 cases).Control group was given conventional diu-retics, angiotensin angiotensin converting enzyme inhibitor (ACEI) or vascular angiotensin II receptor blocker (ARB), and beta blockers, digitalis and nitric acid ester drug treatment .The observation group also added Qiliqiangxin capsule treatment, at the beginning and after 8 weeks treatment , liver function , renal function , myocardial enzyme , clinical curative effect , 6 mi-nutes walking test (6MWT), left ventricular shoot ejection fraction (LVEF), left ventricular diastolic end diastolic diameter (LVEDD), serum N-terminal pro brain natriuretic peptide precursor (NT-proBNP) changes were detected.Results Obser-vation group’s total efficiency was superior to the conventional treatment group (92.2%vs.83.85,χ2 =6.852, P <0.05);2 groups’ LVEF, NT-proBNP were improved than before treatment ( t =4.431, t =51.213, t =6.132, t =71.663, P <0.05), observation group’s NT-proBNP levels were decreased more significantly than control group ( P <0.05).The hepatic function , renal function , myocardial enzymes in two groups before and after the treatment ’ s difference had no statistical signif-icance ( P >0.05).Conclusion Qiliqiangxin capsule effectively improves the clinical symptoms and heart function in eld-erly patients with systolic heart failure , no drug adverse events , worthy of clinical application .